These results suggest that HMGB2 knockdown, when combined with Palbociclib, significantly inhibits the proliferation of a variety of cancer cell lines, demonstrating the potential therapeutic benefit of targeting HMGB2 in combination with cell cycle inhibitors. The gene discussed is HMGB2; the disease is cancer.